Pentokey Organy (India) Limited has scheduled a board meeting for January 21, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The pharmaceutical company made this announcement through a formal communication to BSE Limited on January 16, 2026.

Board Meeting Details

The meeting specifics are outlined in the following table:

Trading Window Status

The company has provided important information regarding its trading window restrictions. Currently, the trading window for dealing in Pentokey Organy securities remains closed in accordance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

The trading window will reopen 48 hours after the financial results for the quarter ended December 31, 2025, become generally available to the public. This standard practice ensures compliance with insider trading regulations and maintains market integrity.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Saurabh Mishra signed the official communication, which was digitally authenticated on January 16, 2026.

The company has also uploaded this intimation on its official website at www.pentokey.com , ensuring transparent communication with all stakeholders. This formal notification allows investors and market participants to prepare for the upcoming financial disclosure and plan their investment decisions accordingly.

Pentokey Organy (India) Limited has announced its financial results for the second quarter of fiscal year 2026, showcasing significant growth across key metrics. The company, which operates in the Pharma/Pesticides trading segment, has demonstrated a remarkable turnaround in its performance compared to the same period last year.

Financial Highlights

All financial figures in Rs. lakhs, except EPS

The company's revenue from operations saw a substantial increase of 346.95%, rising to Rs. 98.33 lakhs from Rs. 22.00 lakhs in the corresponding quarter of the previous year. This growth contributed to a total income of Rs. 108.94 lakhs, marking a 195.47% increase from the Rs. 36.87 lakhs reported in Q2 FY25.

Profitability also improved, with Pentokey Organy posting a net profit of Rs. 14.23 lakhs, up 35.14% from Rs. 10.53 lakhs in the same quarter last year. This improvement is reflected in the basic earnings per share, which increased to Rs. 0.23 from Rs. 0.17 year-on-year.

Half-Year Performance

For the first half of FY26, Pentokey Organy reported revenue of Rs. 604.54 lakhs, a significant jump from Rs. 22.09 lakhs in the previous year's corresponding period. This substantial increase indicates a strong recovery and growth trajectory for the company.

Audit Review and Compliance

The financial results were reviewed and approved at a Board meeting held on November 8, 2025. The company's statutory auditors, A Verma Mehta & Associates, Chartered Accountants, have issued an unmodified limited review report on the quarterly financial results. This review was conducted in accordance with the Standard on Review Engagements (SRE) 2410, as issued by the Institute of Chartered Accountants of India.

Ongoing Tax Matter

It's worth noting that Pentokey Organy has an outstanding income tax demand of Rs. 171.58 lakhs for the assessment year 2015-16. The company has filed an appeal against this demand, which is currently pending resolution.

The strong quarterly performance, particularly the significant revenue growth, suggests that Pentokey Organy may be experiencing increased demand for its products or services in the Pharma/Pesticides trading segment. However, investors should consider both the company's growth trajectory and the pending tax matter when evaluating its overall financial position.